U.S. Implements New Tariff Measures on Pharmaceuticals under Section 232
On April 2, 2026, the United States government issued a presidential proclamation establishing measures to adjust imports of pharmaceutical products and active pharmaceutical ingredients (APIs) under Section 232 of the Trade Expansion Act, citing risks to national security.
Background and rationale
U.S. authorities determined that there is a significant reliance on imported pharmaceuticals, both finished products and APIs, which could jeopardize access to essential medicines in the event of global supply chain disruptions. Currently:
Over 50% of patented pharmaceuticals consumed in the U.S. are produced abroad.
Only about 15% of APIs are domestically manufactured.
Key measures
100% ad valorem tariff on imports of patented pharmaceuticals and related ingredients (Annex I).
Reduced 20% tariff for companies with approved onshoring plans, increasing to 100% within four years.
0% tariff exemption for companies with active or pending agreements related to Most-Favored-Nation (MFN) pricing and domestic production commitments.
Preferential treatment for certain jurisdictions (e.g., EU, Japan, Korea, Switzerland, and Liechtenstein), with reduced tariff rates (e.g., 15%).
Exclusion of generic pharmaceuticals, which are not subject to these measures at this time.
Effective dates
The measures will take effect on:
July 31, 2026, for specific listed companies.
September 29, 2026, for all other importers.
Implications for businesses
Significant increase in import costs for patented pharmaceutical products.
Strong incentives to relocate production to the United States.
Need to reassess supply chain strategies, compliance, and cost structures.
Potential disruptions across global value chains, particularly in North America.
Conclusion
These actions reinforce the U.S. strategy of aligning trade policy with national security objectives, using tariff mechanisms to promote domestic manufacturing and strengthen supply chain resilience.
Decisiones estratégicas en Comercio Exterior con respaldo experto
En un entorno cambiante y altamente regulado, tomar decisiones en Comercio Exterior sin el respaldo adecuado puede generar riesgos, multas y pérdida de beneficios.
En AudiCo ofrecemos Consultoría Especializada, un servicio diseñado para brindarte respuestas claras, fundamentadas y estratégicas que te permitan actuar con seguridad y confianza.
✅ Soporte de alto impacto para resolver tus dudas de manera efectiva.
✅ Análisis con fundamentos normativos y mejores prácticas.
✅ Acompañamiento basado en experiencia y casos reales.
✅ Respaldo experto para tomar decisiones precisas y seguras.
